Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$110.73 USD

110.73
3,527,284

-1.73 (-1.54%)

Updated Aug 6, 2025 02:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Should You Invest in the VanEck Biotech ETF (BBH)?

by Zacks Equity Research

Sector ETF report for BBH

Ekta Bagri headshot

Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?

by Ekta Bagri

GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.

Zacks Equity Research

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Atossa Genetics Inc. (ATOS) and Gilead Sciences (GILD) have performed compared to their sector so far this year.

Zacks Equity Research

MRK's Pivotal Study on Two-Drug, Once-Daily HIV Pill Meets Goals

by Zacks Equity Research

Merck posts positive data from two phase III studies evaluating a two-drug, single-tablet regimen of doravirine/islatravir in adults with HIV-1 infection.

Zacks Equity Research

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the most recent trading session, Gilead Sciences (GILD) closed at $91.09, indicating a +0.44% shift from the previous trading day.

Zacks Equity Research

Is SPDR Russell 1000 Yield Focus ETF (ONEY) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for ONEY

Zacks Equity Research

GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer

by Zacks Equity Research

Gilead announces that the FDA grants a second Breakthrough Therapy designation to Trodelvy for the extensive-stage small cell lung cancer indication.

Zacks Equity Research

Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations

by Zacks Equity Research

Pfizer projects total revenues between $61.0 and $64.0 billion with EPS in the range of $2.80 to $3.00.

Zacks Equity Research

Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains

by Zacks Equity Research

GILD and GSK are in the spotlight in the biotech sector with quite a few regulatory and pipeline updates.

Rimmi Singhi headshot

5 High Earnings Yield Value Picks to Buy for 2025

by Rimmi Singhi

Unlock your portfolio value with these high earnings yield value stocks, PBI, GPOR, KINS, NATL and GILD.

Kinjel Shah headshot

4 Big Drug Stocks That May Continue to Outperform in 2025

by Kinjel Shah

Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum in 2025.

Zacks Equity Research

GILD Obtains Positive CHMP Opinion for Liver Disease Drug

by Zacks Equity Research

The CHMP recommends the approval of Gilead's seladelpar in combination with ursodeoxycholic acid for the treatment of primary biliary cholangitis in adults.

Zacks Equity Research

Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases

by Zacks Equity Research

RHHBY wins approval for prefilled syringe of ophthalmology drug Vabysmo for three retinal conditions that can cause blindness.

Zacks Equity Research

Gilead (GILD) Upgraded to Buy: Here's Why

by Zacks Equity Research

Gilead (GILD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) concluded the recent trading session at $91.86, signifying a -0.57% move from its prior day's close.

Zacks Equity Research

CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal

by Zacks Equity Research

Candel stock rallies 68% on meeting the primary goal in a phase III study of CAN-2409 combo therapy compared to SOC radiation therapy for prostate cancer.

Zacks Equity Research

Is Gilead Sciences (GILD) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Equity Research

Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ONEY

Zacks Equity Research

CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study

by Zacks Equity Research

Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy in colorectal cancer patients.

Zacks Equity Research

QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug

by Zacks Equity Research

uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease.

Ekta Bagri headshot

Bristol Myers Stock Surges 36.5% in Six Months: Time to Buy or Sell?

by Ekta Bagri

Bristol Myers stock has witnessed a stupendous rally in the past six months. We believe there is more room for growth, and any dip in the share price can be used as a buying opportunity.

Zacks Equity Research

Editas Stock Rises on Updated Data From SCD Study of Reni-Cel

by Zacks Equity Research

EDIT's stock gains on updated positive safety and efficacy data from the phase I/II/III RUBY study of its lead candidate, reni-cel, for severe SCD.

Zacks Equity Research

KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential

by Zacks Equity Research

Kodiak stock surges as Jefferies upgrades it to a "BUY" rating based on the significant potential of its pipeline candidates for retinal disease indications.

Zacks Equity Research

Lilly Announces New $15B Stock Buyback Plan, Ups Dividend by 15%

by Zacks Equity Research

LLY's board approves a new $15B stock buyback plan and announces a 15% increase in its quarterly dividend.